Patents by Inventor Bhaskar Pallerla

Bhaskar Pallerla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Parenteral unit dosage form of dihydroergotamine
    Patent number: 11819501
    Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: November 21, 2023
    Inventors: Alpesh Goyani, Deepak Singodia, Bhaskar Pallerla, Sudeep Kumar Agrawal, Subhas Balaram Bhowmick, Rajamannar Thennati
  • PARENTERAL UNIT DOSAGE FORM OF DIHYDROERGOTAMINE
    Publication number: 20230338366
    Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
    Type: Application
    Filed: April 24, 2023
    Publication date: October 26, 2023
    Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Alpesh GOYANI, Deepak SINGODIA, Bhaskar PALLERLA, Sudeep Kumar AGRAWAL, Subhas Balaram BHOWMICK, Rajamannar THENNATI
  • PARENTERAL UNIT DOSAGE FORM OF DIHYDROERGOTAMINE
    Publication number: 20220226308
    Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
    Type: Application
    Filed: April 4, 2022
    Publication date: July 21, 2022
    Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Alpesh GOYANI, Deepak SINGODIA, Bhaskar PALLERLA, Sudeep Kamar AGRAWAL, Subhas Balaram BHOWMICK, Rajamannar THENNATI
  • Parenteral unit dosage form of dihydroergotamine
    Patent number: 11304942
    Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: April 19, 2022
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Alpesh Goyani, Deepak Singodia, Bhaskar Pallerla, Sudeep Kumar Agrawal, Subhas Balaram Bhowmick, Rajamannar Thennati
  • PARENTERAL UNIT DOSAGE FORM OF DIHYDROERGOTAMINE
    Publication number: 20200108061
    Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
    Type: Application
    Filed: December 6, 2019
    Publication date: April 9, 2020
    Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Alpesh GOYANI, Deepak SINGODIA, Bhaskar PALLERLA, Sudeep Kumar AGRAWAL, Subhas Balaram BHOWMICK, Rajamannar THENNATI
  • Parenteral unit dosage form of dihydroergotamine
    Patent number: 10532049
    Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 14, 2020
    Assignee: Pharmaceutical Industries Limited
    Inventors: Alpesh Goyani, Deepak Singodia, Bhaskar Pallerla, Sudeep Kumar Agrawal, Subhas Balaram Bhowmick, Rajamannar Thennati